Lyell Operating Income vs Research Development Analysis

LYEL Stock

USD 1.17 0.04 3.31%

Lyell Immunopharma financial indicator trend analysis is infinitely more than just investigating Lyell Immunopharma recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lyell Immunopharma is a good investment. Please check the relationship between Lyell Immunopharma Operating Income and its Research Development accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyell Immunopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.

Operating Income vs Research Development

Operating Income vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lyell Immunopharma Operating Income account and Research Development. At this time, the significance of the direction appears to have pay attention.

The correlation between Lyell Immunopharma's Operating Income and Research Development is -0.96. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Research Development in the same time period over historical financial statements of Lyell Immunopharma, assuming nothing else is changed. The correlation between historical values of Lyell Immunopharma's Operating Income and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of Lyell Immunopharma are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Operating Income i.e., Lyell Immunopharma's Operating Income and Research Development go up and down completely randomly.

Correlation Coefficient

-0.96

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Operating Income

Operating Income is the amount of profit realized from Lyell Immunopharma operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Lyell Immunopharma is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Research Development

Most indicators from Lyell Immunopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lyell Immunopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyell Immunopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.At this time, Lyell Immunopharma's Selling General Administrative is quite stable compared to the past year. Sales General And Administrative To Revenue is expected to rise to 541.02 this year, although the value of Issuance Of Capital Stock will most likely fall to 0.00.

	2021	2022	2023	2024 (projected)
Interest Income	1.2M	7.1M	23.5M	24.6M
Net Interest Income	1.2M	7.1M	23.5M	24.6M

Interest Income Net Interest Income

Lyell Immunopharma fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital
Total Assets		0.94	0.33	0.95	0.99	-0.6	0.76	0.95	0.5	-0.67	-0.76	0.49	0.87	0.98	0.81	0.68	0.96	0.8	0.28	0.6	-0.21	0.94	0.89	0.61	0.13	0.78
Short Long Term Debt Total	0.94		0.07	0.91	0.97	-0.8	0.87	1.0	0.75	-0.51	-0.91	0.5	0.76	0.87	0.94	0.88	0.97	0.91	0.35	0.71	-0.5	1.0	0.93	0.8	-0.17	0.86
Other Current Liab	0.33	0.07		0.37	0.24	0.54	-0.22	0.1	-0.53	-0.7	0.3	0.3	0.51	0.47	-0.22	-0.28	0.14	-0.22	-0.54	-0.25	0.8	0.05	0.03	-0.53	0.95	-0.06
Total Current Liabilities	0.95	0.91	0.37		0.94	-0.55	0.63	0.91	0.45	-0.58	-0.72	0.72	0.79	0.91	0.73	0.64	0.95	0.7	0.3	0.66	-0.17	0.89	0.75	0.54	0.19	0.6
Total Stockholder Equity	0.99	0.97	0.24	0.94		-0.68	0.82	0.98	0.6	-0.62	-0.82	0.47	0.84	0.95	0.87	0.76	0.97	0.85	0.3	0.65	-0.32	0.97	0.93	0.69	0.01	0.83
Other Liab	-0.6	-0.8	0.54	-0.55	-0.68		-0.86	-0.78	-0.95	0.01	0.95	-0.24	-0.34	-0.46	-0.93	-0.91	-0.74	-0.9	-0.63	-0.75	0.9	-0.81	-0.76	-1.0	0.71	-0.75
Net Tangible Assets	0.76	0.87	-0.22	0.63	0.82	-0.86		0.86	0.77	-0.47	-0.94	0.05	0.71	0.72	0.92	0.88	0.76	0.99	0.49	0.46	-0.64	0.89	0.94	0.89	-0.43	0.95
Property Plant And Equipment Net	0.95	1.0	0.1	0.91	0.98	-0.78	0.86		0.73	-0.52	-0.9	0.49	0.77	0.89	0.94	0.87	0.97	0.9	0.32	0.7	-0.48	1.0	0.94	0.79	-0.14	0.86
Current Deferred Revenue	0.5	0.75	-0.53	0.45	0.6	-0.95	0.77	0.73		0.1	-0.86	0.26	0.2	0.35	0.91	0.93	0.66	0.8	0.37	0.76	-0.93	0.76	0.71	0.93	-0.75	0.72
Net Debt	-0.67	-0.51	-0.7	-0.58	-0.62	0.01	-0.47	-0.52	0.1		0.29	-0.06	-0.93	-0.81	-0.29	-0.24	-0.45	-0.44	0.12	0.18	-0.35	-0.51	-0.58	-0.05	-0.56	-0.56
Retained Earnings	-0.76	-0.91	0.3	-0.72	-0.82	0.95	-0.94	-0.9	-0.86	0.29		-0.33	-0.59	-0.66	-0.95	-0.95	-0.83	-0.97	-0.59	-0.67	0.75	-0.92	-0.86	-0.96	0.5	-0.84
Accounts Payable	0.49	0.5	0.3	0.72	0.47	-0.24	0.05	0.49	0.26	-0.06	-0.33		0.21	0.4	0.32	0.33	0.59	0.17	0.09	0.65	-0.06	0.46	0.16	0.19	0.22	0.0
Cash	0.87	0.76	0.51	0.79	0.84	-0.34	0.71	0.77	0.2	-0.93	-0.59	0.21		0.94	0.58	0.51	0.72	0.7	0.15	0.14	0.06	0.77	0.79	0.38	0.33	0.74
Non Current Assets Total	0.98	0.87	0.47	0.91	0.95	-0.46	0.72	0.89	0.35	-0.81	-0.66	0.4	0.94		0.71	0.58	0.88	0.74	0.18	0.43	-0.05	0.87	0.86	0.48	0.27	0.76
Non Currrent Assets Other	0.81	0.94	-0.22	0.73	0.87	-0.93	0.92	0.94	0.91	-0.29	-0.95	0.32	0.58	0.71		0.96	0.88	0.95	0.41	0.74	-0.74	0.95	0.93	0.93	-0.46	0.9
Other Assets	0.68	0.88	-0.28	0.64	0.76	-0.91	0.88	0.87	0.93	-0.24	-0.95	0.33	0.51	0.58	0.96		0.76	0.91	0.33	0.64	-0.79	0.9	0.84	0.91	-0.54	0.85
Cash And Short Term Investments	0.96	0.97	0.14	0.95	0.97	-0.74	0.76	0.97	0.66	-0.45	-0.83	0.59	0.72	0.88	0.88	0.76		0.82	0.4	0.79	-0.4	0.96	0.86	0.73	-0.06	0.74
Common Stock Total Equity	0.8	0.91	-0.22	0.7	0.85	-0.9	0.99	0.9	0.8	-0.44	-0.97	0.17	0.7	0.74	0.95	0.91	0.82		0.53	0.55	-0.67	0.93	0.93	0.92	-0.43	0.93
Common Stock Shares Outstanding	0.28	0.35	-0.54	0.3	0.3	-0.63	0.49	0.32	0.37	0.12	-0.59	0.09	0.15	0.18	0.41	0.33	0.4	0.53		0.43	-0.5	0.35	0.27	0.64	-0.47	0.22
Short Term Investments	0.6	0.71	-0.25	0.66	0.65	-0.75	0.46	0.7	0.76	0.18	-0.67	0.65	0.14	0.43	0.74	0.64	0.79	0.55	0.43		-0.62	0.69	0.53	0.71	-0.38	0.4
Non Current Liabilities Total	-0.21	-0.5	0.8	-0.17	-0.32	0.9	-0.64	-0.48	-0.93	-0.35	0.75	-0.06	0.06	-0.05	-0.74	-0.79	-0.4	-0.67	-0.5	-0.62		-0.52	-0.49	-0.88	0.93	-0.54
Capital Lease Obligations	0.94	1.0	0.05	0.89	0.97	-0.81	0.89	1.0	0.76	-0.51	-0.92	0.46	0.77	0.87	0.95	0.9	0.96	0.93	0.35	0.69	-0.52		0.94	0.82	-0.19	0.88
Other Current Assets	0.89	0.93	0.03	0.75	0.93	-0.76	0.94	0.94	0.71	-0.58	-0.86	0.16	0.79	0.86	0.93	0.84	0.86	0.93	0.27	0.53	-0.49	0.94		0.78	-0.21	0.97
Other Stockholder Equity	0.61	0.8	-0.53	0.54	0.69	-1.0	0.89	0.79	0.93	-0.05	-0.96	0.19	0.38	0.48	0.93	0.91	0.73	0.92	0.64	0.71	-0.88	0.82	0.78		-0.7	0.78
Total Liab	0.13	-0.17	0.95	0.19	0.01	0.71	-0.43	-0.14	-0.75	-0.56	0.5	0.22	0.33	0.27	-0.46	-0.54	-0.06	-0.43	-0.47	-0.38	0.93	-0.19	-0.21	-0.7		-0.31
Net Invested Capital	0.78	0.86	-0.06	0.6	0.83	-0.75	0.95	0.86	0.72	-0.56	-0.84	0.0	0.74	0.76	0.9	0.85	0.74	0.93	0.22	0.4	-0.54	0.88	0.97	0.78	-0.31

Click cells to compare fundamentals

Lyell Immunopharma Account Relationship Matchups

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Lyell Immunopharma is a strong investment it is important to analyze Lyell Immunopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lyell Immunopharma's future performance. For an informed investment choice regarding Lyell Stock, refer to the following important reports:

How To Invest In Lyell

Details

Is Lyell Stock a good investment?

Details

What is Lyell Immunopharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyell Immunopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.

You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.79)

Quarterly Revenue Growth

0.36

Return On Assets

(0.19)

Return On Equity

(0.33)

The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lyell Operating Income vs Research Development Analysis

Operating Income vs Research Development

Operating Income vs Research Development Correlation Analysis

Correlation Coefficient

Operating Income

Research Development

Lyell Immunopharma fundamental ratios Correlations

Lyell Immunopharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Net	+ 1.0	Short Long Term Debt Total
Capital Lease Obligations	+ 1.0	Short Long Term Debt Total
Capital Lease Obligations	+ 1.0	Property Plant And Equipment Net
Total Stockholder Equity	+ 0.99	Total Assets
Common Stock Total Equity	+ 0.99	Net Tangible Assets
Non Current Assets Total	+ 0.98	Total Assets

Other Stockholder Equity	- 1.0	Other Liab
Common Stock Total Equity	- 0.97	Retained Earnings
Other Stockholder Equity	- 0.96	Retained Earnings
Other Assets	- 0.95	Retained Earnings
Non Currrent Assets Other	- 0.95	Retained Earnings
Current Deferred Revenue	- 0.95	Other Liab